Transgene Biotek Board Meeting on Nov 13 to Approve Q2 Results

Transgene Biotek Ltd has announced a Board of Directors meeting scheduled for November 13, 2026. The meeting will primarily focus on approving the Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half-yearly ended September 30, 2026, along with the Limited Review Report. Additionally, the board will consider and approve the Notice and Board's Report for the 36th Annual General Meeting (AGM) for FY 2025-26, including setting the Record Date, Book Closure period, and e-voting dates. The re-appointment of Dr. K. Koteswara Rao as Chairman & Managing Director for a further one-year term will also be discussed, subject to shareholder approval. The trading window for securities remains closed until 48 hours after the financial results are published.